Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort

on behalf of the PROMPT study group

doi:10.1093/rheumatology/kex323

Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort

on behalf of the PROMPT study group

Department of Mathematics

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2109-2113
Number of pages	5
Journal	Rheumatology (United Kingdom)
Volume	56
Issue number	12
DOIs	https://doi.org/10.1093/rheumatology/kex323
Publication status	Published - 1 Dec 2017

Keywords

Diagnosis
Epidemiology
Incidence
Psoriasis
Psoriatic arthritis

Access to Document

10.1093/rheumatology/kex323

Cite this

@article{bb90abac557842c58b1c72fb1a4238f7,

title = "Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort",

keywords = "Diagnosis, Epidemiology, Incidence, Psoriasis, Psoriatic arthritis",

author = "{on behalf of the PROMPT study group} and William Tillett and Rachel Charlton and Alison Nightingale and Julia Snowball and Amelia Green and Catherine Smith and Gavin Shaddick and Neil McHugh and Sarah Hewlett and Helen Harris and Philip Helliwell and Laura Coates and Catherine Fernandez and Sarah Brown and Claire Davies and Jonathan Packham and Laura Bjoke and Eldon Spakman and Anne Barton and Oliver Fitzgerald and Vishnu Madhok and Melanie Brooke and Jana James and Andrew Parkinson",

note = "Funding Information: Funding: This report is independent research funded by the National Institute for Health Research [Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis (grant number RP-PG-1212-20007)]. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health. Funding Information: Disclosure statement: A.N. Reports grants from Pfizer and Celgene outside the submitted work. C.S. has received departmental funding from manufacturers of drugs used to treat psoriasis and psoriatic arthritis including AbbVie, Pfizer, Novartis, Roche, Regeneron and Janssen. All other authors have declared no conflicts of interest. Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.",

year = "2017",

month = dec,

day = "1",

doi = "10.1093/rheumatology/kex323",

language = "English",

volume = "56",

pages = "2109--2113",

journal = "Rheumatology (United Kingdom)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort

AU - on behalf of the PROMPT study group

AU - Tillett, William

AU - Charlton, Rachel

AU - Nightingale, Alison

AU - Snowball, Julia

AU - Green, Amelia

AU - Smith, Catherine

AU - Shaddick, Gavin

AU - McHugh, Neil

AU - Hewlett, Sarah

AU - Harris, Helen

AU - Helliwell, Philip

AU - Coates, Laura

AU - Fernandez, Catherine

AU - Brown, Sarah

AU - Davies, Claire

AU - Packham, Jonathan

AU - Bjoke, Laura

AU - Spakman, Eldon

AU - Barton, Anne

AU - Fitzgerald, Oliver

AU - Madhok, Vishnu

AU - Brooke, Melanie

AU - James, Jana

AU - Parkinson, Andrew

N1 - Funding Information: Funding: This report is independent research funded by the National Institute for Health Research [Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis (grant number RP-PG-1212-20007)]. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health. Funding Information: Disclosure statement: A.N. Reports grants from Pfizer and Celgene outside the submitted work. C.S. has received departmental funding from manufacturers of drugs used to treat psoriasis and psoriatic arthritis including AbbVie, Pfizer, Novartis, Roche, Regeneron and Janssen. All other authors have declared no conflicts of interest. Publisher Copyright: © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

PY - 2017/12/1

Y1 - 2017/12/1

KW - Diagnosis

KW - Epidemiology

KW - Incidence

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85037723528&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kex323

DO - 10.1093/rheumatology/kex323

M3 - Article

C2 - 28968790

AN - SCOPUS:85037723528

SN - 1462-0324

VL - 56

SP - 2109

EP - 2113

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

IS - 12

ER -

Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort

Keywords

Access to Document

Other files and links

Cite this